Alto Neuroscience (NYSE:ANRO) Price Target Raised to $26.00

Alto Neuroscience (NYSE:ANRO) had its price objective hoisted by Wedbush from $24.00 to $26.00 in a research report sent to investors on Thursday,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other equities analysts also recently weighed in on ANRO. Weiss Ratings restated a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. Bank of America initiated coverage on shares of Alto Neuroscience in a research note on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target for the company. HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a research report on Wednesday, June 17th. Wall Street Zen lowered shares of Alto Neuroscience from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $36.62.

Alto Neuroscience Stock Down 0.5%

ANRO stock opened at $32.14 on Thursday. The company has a quick ratio of 20.52, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. The business has a 50 day moving average price of $25.97 and a two-hundred day moving average price of $22.75. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -13.28 and a beta of 1.06. Alto Neuroscience has a twelve month low of $3.05 and a twelve month high of $33.67.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.08. Analysts anticipate that Alto Neuroscience will post -3 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC bought a new position in Alto Neuroscience during the first quarter worth $52,000. Torren Management LLC bought a new position in shares of Alto Neuroscience in the fourth quarter valued at about $62,000. Invesco Ltd. bought a new position in shares of Alto Neuroscience in the first quarter valued at about $67,000. Bridgeway Capital Management LLC lifted its stake in shares of Alto Neuroscience by 85.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after buying an additional 25,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Alto Neuroscience during the 4th quarter worth about $198,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.